Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, C4 Therapeutics Inc’s stock clocked out at $2.47, down -2.76% from its previous closing price of $2.54. In other words, the price has decreased by -$2.76 from its previous closing price. On the day, 1.29 million shares were traded. CCCC stock price reached its highest trading level at $2.57 during the session, while it also had its lowest trading level at $2.46.
Ratios:
To gain a deeper understanding of CCCC’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.76 and its Current Ratio is at 5.76. In the meantime, Its Debt-to-Equity ratio is 0.40 whereas as Long-Term Debt/Eq ratio is at 0.36.
On September 17, 2025, Barclays started tracking the stock assigning a Overweight rating and target price of $8.
Stephens Upgraded its Equal-Weight to Overweight on September 15, 2025, while the target price for the stock was maintained at $6.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Feb 18 ’25 when Boyle Scott N sold 669 shares for $3.15 per share. The transaction valued at 2,107 led to the insider holds 107,805 shares of the business.
Boyle Scott N sold 490 shares of CCCC for $1,544 on Feb 14 ’25. The Chief Business Officer now owns 110,842 shares after completing the transaction at $3.15 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CCCC now has a Market Capitalization of 239378608 and an Enterprise Value of 108957616. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.95 while its Price-to-Book (P/B) ratio in mrq is 1.19. Its current Enterprise Value per Revenue stands at 3.619 whereas that against EBITDA is -0.931.
Stock Price History:
The Beta on a monthly basis for CCCC is 2.91, which has changed by -0.41067284 over the last 52 weeks, in comparison to a change of 0.13613915 over the same period for the S&P500. Over the past 52 weeks, CCCC has reached a high of $4.70, while it has fallen to a 52-week low of $1.09. The 50-Day Moving Average of the stock is 1.01%, while the 200-Day Moving Average is calculated to be 18.30%.
Shares Statistics:
It appears that CCCC traded 2.08M shares on average per day over the past three months and 1656300 shares per day over the past ten days. A total of 96.91M shares are outstanding, with a floating share count of 78.37M. Insiders hold about 19.13% of the company’s shares, while institutions hold 57.44% stake in the company. Shares short for CCCC as of 1764288000 were 5588028 with a Short Ratio of 2.68, compared to 1761868800 on 4811669. Therefore, it implies a Short% of Shares Outstanding of 5588028 and a Short% of Float of 6.1.
Earnings Estimates
. The current assessment of C4 Therapeutics Inc (CCCC) involves the perspectives of 3.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is -$0.31, with high estimates of -$0.27 and low estimates of -$0.35.
Analysts are recommending an EPS of between -$1.33 and -$1.71 for the fiscal current year, implying an average EPS of -$1.52. EPS for the following year is -$1.29, with 3.0 analysts recommending between -$1.15 and -$1.55.
Revenue Estimates
In. The current quarter, 5 analysts expect revenue to total $4.48M. It ranges from a high estimate of $8M to a low estimate of $100k. As of. The current estimate, C4 Therapeutics Inc’s year-ago sales were $5.18M
A total of 6 analysts have provided revenue estimates for CCCC’s current fiscal year. The highest revenue estimate was $35M, while the lowest revenue estimate was $25M, resulting in an average revenue estimate of $30.39M. In the same quarter a year ago, actual revenue was $35.58M
